TriSalus Life Sciences, Inc. Warrant (TLSIW) Stock Price

TLSIWStock

$0.88

Market Cap—

P/E—

PEG Ratio—

Div yield—

Beta1.86

TLSIW Share Price Chart

Favorite Metrics

Price vs S&P 500 (26W)-45.00%

Price vs S&P 500 (4W)58.45%

VGM Score60.83

Industry Peers — Surgical & Medical Instruments(142)

Symbol	Value Score	Growth Score	Momentum Score	P/S Ratio (TTM)	Revenue Growth (5Y)	Gross Margin (TTM)	Operating Margin (TTM)	Price
TLSIWTriSalus Life Sciences, Inc. Warrant	—	—	B	—	—	—	—	$0.88
SYKStryker Corporation	C	B	C	4.4x	11.8%	65.3%	21.3%	$294.66
MMM3M Company	C	D	B	3.4x	-5.0%	39.4%	18.4%	$164.75
BSXBoston Scientific Corp.	C	B	C	3.1x	15.2%	69.5%	19.8%	$44.39
BDXBecton, Dickinson and Co.	B	D	A	2.5x	6.3%	46.7%	9.6%	$191.75
MDLNMedline Inc. Class A common stock	C	D	C	1.6x	—	26.2%	6.0%	$35.96
RMDResMed Inc.	C	C	B	5.9x	12.1%	61.1%	33.4%	$238.97
DXCMDexCom, Inc.	C	B	B	6.5x	19.3%	64.3%	22.9%	$86.04
WSTWest Pharmaceutical Services, Inc.	D	C	A	8.5x	7.4%	36.8%	20.4%	$384.02
SOLVSolventum Corporation	C	C	B	1.8x	—	54.8%	23.9%	$85.81
BAXBaxter International Inc.	B	D	B	1.1x	-0.8%	30.7%	-2.3%	$25.28
PENPenumbra, Inc.	F	C	B	8.4x	20.2%	67.8%	12.4%	$320.86
GMEDGLOBUS MEDICAL INC	B	B	B	3.3x	30.1%	68.5%	20.6%	$76.71
PODDInsulet Corporation	C	A	C	3.2x	24.5%	71.1%	16.9%	$141.10
GKOSGlaukos Corporation	F	A	B	15.9x	17.7%	79.1%	-31.6%	$164.84
TFXTeleflex Incorporated	B	F	B	2.1x	-4.7%	53.8%	-11.7%	$130.43
HAEHaemonetics Corporation	C	C	A	4.0x	8.9%	59.1%	11.9%	$118.28
MMSIMerit Medical Systems Inc	C	B	B	3.4x	9.5%	49.5%	12.8%	$89.20
STVNStevanato Group S.p.A.	D	C	C	3.7x	12.4%	29.9%	16.4%	$18.90
MMEDMiniMed Group, Inc. Common Stock	—	—	B	—	—	—	—	$17.49
HTFLHeartflow, Inc. Common Stock	F	A	A	19.8x	—	80.1%	-40.8%	$48.29
ICUIICU Medical Inc	C	D	B	1.9x	11.9%	39.1%	3.5%	$162.99
IRTCiRhythm Holdings, Inc. Common Stock	D	B	C	4.3x	23.0%	71.5%	-3.0%	$108.66
PLSEPulse Biosciences, Inc Common Stock (DE)	F	—	A	2725.9x	—	0.3%	-7007.8%	$44.43
ATRCAtriCure, Inc.	D	B	A	5.0x	20.9%	76.3%	2.3%	$56.07
UFPTUFP Technologies Inc	C	B	A	3.6x	27.4%	28.5%	15.3%	$291.67
INSPInspire Medical Systems, Inc.	B	B	B	2.2x	51.2%	86.1%	6.0%	$68.79
LMATLeMaitre Vascular, Inc.	C	B	C	7.0x	14.0%	72.9%	29.5%	$80.82
NVCRNovoCure Limited Ordinary Shares	D	C	C	2.3x	5.8%	76.1%	-22.1%	$14.07
KMTSKestra Medical Technologies, Ltd. Common Stock	F	A	B	15.2x	—	53.9%	-140.4%	$27.24
ATECAlphatec Holdings, Inc.	D	B	C	2.0x	39.5%	70.8%	-7.5%	$10.46
DRTSAlpha Tau Medical Ltd. Ordinary Shares	—	—	B	—	—	—	—	$12.29
TNDMTandem Diabetes Care, Inc.	D	C	C	1.1x	15.3%	56.0%	-4.4%	$16.24
IRMDiRadimed Corporation	D	B	B	13.1x	21.4%	75.9%	31.9%	$88.27
AORTArtivion, Inc.	C	C	C	2.3x	11.8%	64.4%	2.9%	$21.78
IARTIntegra LifeSciences Holdings	B	F	C	0.6x	3.6%	57.2%	4.0%	$13.21
PRCTPROCEPT BioRobotics Corporation Common Stock	C	A	D	3.0x	109.0%	64.2%	-33.9%	$17.57
BVSBioventus Inc. Class A Common Stock	B	C	A	1.9x	12.1%	68.7%	10.0%	$13.30
BBNXBeta Bionics, Inc. Common Stock	D	A	C	7.4x	—	58.3%	-69.8%	$16.35
SIBNSI-BONE, Inc. Common Stock	D	B	B	4.1x	22.3%	79.5%	-8.3%	$19.68
SGPSpyGlass Pharma, Inc. Common Stock	—	—	B	—	—	—	—	$24.00
MDXGMiMedx Group, Inc	C	D	C	1.8x	11.0%	78.8%	2.5%	$4.43
KIDSOrthoPediatrics Corp. Common Stock	C	B	B	2.3x	27.2%	73.7%	-11.9%	$21.95
TCMDTactile Systems Technology, Inc.	B	B	B	1.5x	12.0%	51.9%	10.0%	$22.52
SSIISS Innovations International Inc. Common Stock	F	A	D	9.7x	—	47.6%	-16.2%	$2.53
DCTHDelcath Systems Inc	D	C	B	5.1x	120.1%	87.0%	-1.9%	$14.08
ANGOAngioDynamics, Inc.	C	D	C	1.5x	1.9%	55.6%	-11.2%	$11.24
BWAYBrainsway Ltd. American Depositary Shares	D	B	B	9.5x	12.2%	74.9%	5.8%	$11.44
SGHTSight Sciences, Inc. Common Stock	D	B	A	5.5x	22.9%	88.4%	-33.4%	$8.28
CERSCerus Corp	D	C	C	1.8x	15.4%	57.2%	-0.7%	$2.18
NPCENeuropace, Inc. Common Stock	D	C	C	4.3x	19.4%	79.6%	-15.3%	$12.24

About TriSalus Life Sciences, Inc. Warrant

TriSalus Life Sciences develops drug delivery systems and immune-oncology therapeutics targeting difficult-to-treat liver and pancreatic cancers. The company markets PEDD (Pressure Enabled Drug Delivery) infusion systems, including its latest TriNav device with SmartValve technology, which are in clinical use today. It is also advancing nelitolimod (SD-101), an investigational agent designed to enhance immune response against hepatocellular carcinoma, pancreatic cancer, and other liver tumors.